FDA accepts Spectrum's Zevalin response

The FDA has accepted for review Spectrum Pharmaceuticals' response on the experimental cancer drug Zevalin as a Class 1 submission, setting a deadline of September 7 for its final decision. That's the kind of news that investors were looking for. Spectrum's stock surged on the news. The agency had asked for more data from Spectrum, which is looking to gain approval to use Zevalin to treat non-Hodgkins lymphoma. Report